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The aging population, the fastest growing sector of the
general population in the Western world, is also rapidly
increasing in Taiwan. The proportion of elderly in Taiwan
has grown from 6.93% of the total population at the end
of 1993 to 8.62% in 2000 and to 9.6% in 2005. If current
trends continue, it is predicted to reach 10.44% by the
year 20101. Given the demographic shift, we can expect
an increasing number of elderly patients with both acute
and chronic renal failure. Deaths due to renal disease in
the elderly in Taiwan have increased gradually, account-
ing for 4.30% of all causes of mortality in 2005. A number
of factors may contribute to the increased incidence of
acute renal failure (ARF) in older individuals. Because
of structural and functional alterations2,3, the aging
kidney is less able to adapt to rapid hemodynamic
changes and changes in salt and water balance. The
elderly are also subject to a number of chronic systemic
diseases such as hypertension, diabetes mellitus, athero-
sclerosis, heart disease, and malignancy. Some of these
result in direct kidney damage, while others may be
superimposed on or complicate pre-existing renal dis-
ease. Compared with younger individuals, the elderly
consume twice as many medications, some of which
are nephrotoxic, and may be more sensitive to them.
For example, if there is already a decrease in renal
reserve, there is a higher risk of renal failure with diag-
nostic contrast medium as compared with younger
people.
Depending on its severity, ARF may require renal
replacement therapy. In patients who are hemodynami-
cally unstable, continuous renal replacement therapy
(CRRT) is preferred over intermittent dialysis. Given their
frequent comorbidities, the elderly may be at a higher
risk of hemodynamic instability and therefore more
likely to undergo CRRT. We reviewed the literature deal-
ing with CRRT in the elderly. We searched MEDLINE with
the terms “acute renal failure”, “elderly”, “continuous
renal replacement therapy”, and “dialysis”. We primarily
selected articles published in the last 5 years, but did
not exclude commonly referenced and highly regarded
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older publications. We also searched the reference lists
of articles identified by these strategies and selected
those judged relevant, including both review articles
and book chapters. There was no restriction on the
language of publication.
Our review is focused on the causes and prognosis of
ARF in the elderly, which are essential to understanding
the impact of ARF in these patients. We also review the
principles of CRRT in this particular demographic group.
Clinicians should be familiar with this treatment modal-
ity as the need for it will most likely increase.
Aging and the Kidney
The main characteristic of the aging kidney is a limita-
tion of the adaptive renal response to various threats.
This lower renal reserve means that elderly individuals
are more prone to develop ARF under high-risk cir-
cumstances than younger people4,5. If there is already
a pre-existing impairment in renal function, any new
insult may further damage the kidneys. Understanding
the functional and structural changes in the aging 
kidney helps explain why this is the case.
Functional changes
The kidney has an autoregulatory function to adapt 
to low renal perfusion pressures by preserving renal
blood flow and glomerular filtration rate (GFR) at rela-
tively constant levels. With increasing age, this function
declines6–8. The ability of the elderly kidney to maintain
urine concentration, acid-base balance, and normal
renin/aldosterone activity is also impaired9,10. Thus,
electrolyte disturbances and deterioration of GFR are
common in elderly patients admitted to the hospital for
a variety of systemic diseases.
Structural changes
As we age, it can be seen microscopically that the
nephrons become smaller11 and macroscopically that
there is gross atrophy of the kidney. By about the age of
30 years, some glomeruli are already partially or totally
sclerosed12. There are additional microscopic changes,
including in the tubules, interstitium, and renal ves-
sels. Between the ages of 30 and 90 years, the average
renal weight decreases by 20–30%, from 200–270 g to
180–200 g13. Because of these age-associated changes,
theoretically, even a modest reduction in renal function
can seriously threaten an elderly patient.
Incidence of ARF in the Aging Population
The true incidence of ARF is difficult to estimate because
more than 30 definitions have been used in various
studies14. Generally, ARF is defined as a rapid (i.e., over
hours to weeks) and usually reversible decline in the
GFR15,16. The Acute Dialysis Quality Initiative group has
developed a useful classification system and definitions
for ARF and acute-on-chronic renal failure17. Because
the definitions do vary, it must be admitted that pub-
lished incidence figures may not be exact. However, the
relative trend is clear: ARF is considerably more com-
mon in the elderly than in younger people. In a 2-year
prospective study in England, it was found that indi-
viduals above 70 years of age comprised more than
70% of all those with severe ARF. The incidence was 17
per million in those below 50 years of age but 949 per
million in those aged 80–89 years18. A similar study in
Spain found that the incidence of ARF in patients aged
above 80 years was 1,129 cases per million19.
Causes of ARF in the Elderly
The causes of ARF in the elderly have been extensively
discussed19–22 and generally fall into 3 major cate-
gories: prerenal, intrinsic, and obstructive3. In a retro-
spective series of 381 patients above 80 years of age
with ARF reported by Akposso et al.23, 24.1% had prere-
nal, 53.5% had intrinsic, and 22.3% had obstructive
causes of ARF. Etiologies of prerenal ARF in this series
were primarily extracellular dehydration (59.7%) and
heart failure (15.4%). Intrinsic renal failure was attrib-
utable to shock (49.1%), nephrotoxic drugs (6%), rhab-
domyolysis (9.8%), and multiple myeloma (6.8%).
Obstructive renal failure was predominantly caused by
prostatic tumors (48.4%) and malignant pelvic tumors
such as bladder cancer, ovarian or uterine cancer, and
colorectal cancer.
Prognosis of ARF in the Elderly
Among elderly patients, ARF frequently occurs in the
setting of critical illness, e.g., medical or surgical com-
plications and multiple organ failure. The mortality in
such patients is high, reportedly ranging from 40% to
80%23–28. Various factors have been identified as predic-
tors of mortality in elderly patients with ARF. The worst
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prognostic factors identified by Sesso et al.28 and oth-
ers29–31 are cardiac disease, organ failure, mechanical
ventilation, malignancy, oliguria, and requirement for
dialysis. However, there is no clear consensus as to
whether age per se is an independent risk factor. A study
by Druml et al.32 failed to show any relationship between
advanced age and outcome of ARF, a finding echoed by
other groups4,33. The most recent analysis of prognosis
of ARF in the very old (>80 years) showed a slightly but
significantly higher mortality than in an age-matched
control population without ARF. However, the ARF-
specific mortality in the elderly was no worse than the
overall ARF-specific mortality in the literature23. Thus, it
cannot be concluded that old age is an independent
predictor of a poor outcome, and age therefore should
not be used as a factor in making therapeutic decisions
for ARF when it occurs in the elderly.
Renal Replacement Therapy in the Elderly
In the absence of effective pharmacologic therapy, the
management of ARF is primarily supportive with renal
replacement therapy as needed. This was first suc-
cessfully used for a 67-year-old woman with ARF in
September 194534. The available modalities include peri-
toneal dialysis, intermittent hemodialysis (IHD), CRRT,
and hybrid renal replacement therapies. The optimal
dialytic therapy for ARF in general remains controver-
sial, and there has been little discussion of this ques-
tion specifically focused on elderly patients with ARF.
Although peritoneal dialysis offers some theoreti-
cal advantages, there are several medical and techni-
cal reasons for why it is currently less frequently used.
Conventional IHD in the elderly is complicated in this
population by the prevalence of cardiac and peripheral
vascular disease. These factors make older patients
particularly susceptible to HD-associated hypotension,
among other complications. Hemodynamic instability
and the resulting shortened dialysis time limit the effect
of the dialytic dose. Hybrid, or sustained low-efficiency,
dialysis is an extended dialysis method characterized by
slower blood and dialysate flow rates. The term “hybrid”
indicates that it combines features of both IHD and
CRRT. It can be maintained for prolonged periods, pro-
viding excellent detoxification with cardiovascular sta-
bility and flexible treatment time35–38. However, these
techniques are still largely experimental and are thus
beyond the scope of this article.
CRRT affords better hemodynamic stability than
conventional IHD39 and is, therefore, particularly attrac-
tive for elderly patients with ARF. There are as yet, how-
ever, no controlled studies in this population showing
definite evidence of benefit. In addition, CRRT may be
of benefit in treating nonrenal problems in critically ill
patients40–42. It allows continuous removal of large
fluid volumes or toxic substances, such as cytokines and
chemokines in sepsis, acute respiratory distress syn-
drome, or burns43. Again, however, it should be pointed
out that there is as yet no robust evidence of improved
outcomes in these settings. CRRT is also useful in fluid
control and management of acid-base and electrolyte
imbalances44–46. When IHD is used, time is always a
limiting factor, hence the need for relatively high
blood and dialysate flow rates, which correlate with the
degree of blood purification achieved. CRRT permits
the use of slower flow rates and may achieve weekly
clearances that are equal or even superior to IHD.
These advantages of CRRT must be balanced against
its greater cost in terms of equipment and staff time47.
Definitions and Therapeutic Potential 
of CRRT
In 1977, Kramer et al.48 developed continuous arteri-
ovenous hemofiltration in order to avoid the side effects
of IHD. Today, this particular access method is rarely
used because it carries its own set of adverse effects49.
Additionally, blood flow and ultrafiltration volume are
largely dependent on the patient’s mean arterial pres-
sure. These shortcomings have led to several technical
modifications. CRRT is now generally performed with
a pump50. It may use primarily convective clearance
(continuous venovenous hemofiltration) or diffusive
clearance (continuous venovenous hemodialysis), or it
may involve a combination of these procedures (con-
tinuous venovenous hemodiafiltration). Solute removal
by diffusion is determined by the molecular weight of
the solute, the concentration gradient across the dial-
ysis membrane, and, to a lesser extent, the membrane
surface area. Smaller solutes such as urea, creatinine,
and electrolytes are cleared largely by diffusion, but as
their molecular weight increases, substances are less
likely to be removable by diffusion. Convective clear-
ance depends on the ultrafiltration rate and is rela-
tively independent of molecular size. Convection has
an advantage over diffusion in being able to clear
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middle- or large-molecular weight toxins in patients
with sepsis51. The particular CRRT modality chosen,
then, depends on the substances requiring clearance.
Diffusion is more appropriate if small molecules such
as urea, uric acid, potassium, and creatinine are the
targets, whereas convection is more useful for larger
molecules. However, it must be noted that there is not
yet enough evidence from clinical trials to determine
if these differences at a molecular level actually trans-
late into measurable differences in clinical outcome.
Timing of CRRT Initiation
The generally accepted indications for initiation of CRRT
in ARF include volume overload unresponsive to fluid
restriction and diuretics, hyperkalemia refractory to
medical management, metabolic acidosis that is severe
or accompanied by volume overload that precludes
adequate bicarbonate therapy, overt uremic symptoms
(anorexia, nausea, vomiting) or signs (uremic pericarditis,
bleeding, encephalopathy), or anuric ARF unresponsive
to acute interventions such as reversal of prerenal fac-
tors or relief of obstruction. CRRT is also indicated for
certain dialyzable intoxications (e.g., lithium, toxic alco-
hols, salicylate) and for some cases of hypomagnesemia,
hyperphosphatemia, or hypercalcemia.
Observational studies have suggested that the precise
timing of initiation of CRRT in the elderly may have a
profound effect on outcome, although no randomized
controlled trials have yet specifically addressed this
question. After cardiac surgery, for example, a better
outcome has been observed when CRRT is begun
early52,53. Since the consequences of complications are
likely to be more severe for a critically ill patient, early
initiation of therapy to support organ function may
improve the outcome by providing an opportunity for
the patient to recover from the underlying illness. CRRT
in this setting has the primary goal of providing ade-
quate renal support for other organ functions. This
requires a change in our traditional approach of wait-
ing for specific metabolic or biochemical abnormalities
prior to initiation of dialysis. The broad goals for treat-
ing ARF with dialysis, then, are to: (1) maintain fluid
and electrolyte, acid-base, and solute homeostasis; 
(2) prevent further insult to the kidney; (3) promote
renal recovery; and (4) permit other supportive measures
(e.g., nutrition) that might otherwise be limited in the
presence of ARF54.
Intermittent vs. Continuous Therapy: 
Does it really make a difference?
In theory, it sounds as if CRRT ought to improve survival in
elderly patients with ARF. In fact, however, there is as yet
no hard evidence to support the superiority of CRRT over
IHD in terms of survival27,55–58. Studies that have been
performed have been limited in scope, of relatively poor
quality, or have failed to define subgroups in such a way
as to provide a solid basis for choosing 1 method over
another. Most of the current evidence comes from obser-
vational studies or studies of unselected patients57,59,60.
There have been small studies of specific conditions,
e.g., CRRT provided a slightly greater physiologic benefit
than IHD in treating 12 patients with cerebral edema and
ARF61–63. A distinction should be made between articles
that discuss the theoretical benefit of CRRT61–63 and
those based on rigorous clinical trials. A multicenter,
randomized trial involving 161 patients failed to show
a benefit for CRRT over IHD, but the authors acknowl-
edged the difficulties in designing a trial that uses
clearly defined populations with equivalent treatment
doses and associated treatments56,58,64,65. Other stud-
ies have also failed to show a clear cut benefit for
CRRT56,58,64,65, but none of these have specifically
addressed the value of this treatment in the elderly.
Large-scale randomized trials, which will most likely
have to be multicenter collaborative efforts, are needed
to demonstrate whether the theoretical advantages of
CRRT in fact provide a better outcome for elderly patients
with ARF.
Until such evidence is available, we recommend
CRRT for ARF in patients whose hemodynamic status
makes them unable to tolerate IHD. This is likely to be
the case for many elderly patients with ARF, particularly
in the face of other critical illnesses such as sepsis or
multiple organ failure.
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